Kolexia
Gastaud Lauris Oncologie hémato.
Gastaud Lauris
Oncologie hémato.
Centre Antoine Lacassagne
Nice, France
166 Activités
383 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Mélanome Lymphomes Tumeurs de l'uvée Métastase tumorale Maladie de Hodgkin Syndromes myélodysplasiques

Collaborateurs

Voir plus
Cluzeau Thomas
Cluzeau Thomas
Hôpital De l'Archet, Nice, France
Thyss Antoine
Thyss Antoine
Centre Antoine Lacassagne, Nice, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Abbvie
18 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023
Mylan Medical
5 collaboration(s)
Dernière en 2021
CanceroDigest
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma: A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Essai Clinique (Immunocore Ltd)   06 mars 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
EMBO molecular medicine   15 novembre 2023
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023
Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
65th ASH Annual Meeting Abstracts   02 novembre 2023
Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT
65th ASH Annual Meeting Abstracts   02 novembre 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
The New England journal of medicine   21 octobre 2023
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Essai Clinique (ImmunoGen, Inc.)   04 octobre 2023
Ivosidenib-azacitidine in acute myeloid leukemia with IDH1R132 mutation.
Bulletin du cancer   03 octobre 2023